HPS2-THRIVE trial Among patients with atherosclerotic vascular disease, the addition of extended-release niacin–laropiprant to statin-based LDL cholesterol–lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients — NEJM.
A Form of the Metabolic Syndrome Associated with Mutations in DYRK1B — NEJM. A founder mutation was identified in DYRK1B, substituting cysteine for arginine at position 102 in the highly conserved kinase-like domain. The mutation precisely cosegregated with the clinical syndrome. Functional characterization of the disease gene revealed that nonmutant protein encoded by DYRK1B inhibits […]
Details of topcat trial Pfeffer_TOPCAT
TOPCAT trial shows no benefit of spironolactone in terms of death, hospitalization, aborted SCD in heart failure with preserved ejection fraction. Spironolactone for Heart Failure with Preserved Ejection Fraction — NEJM.